Ameritas Investment Partners
NRIX icon

Ameritas Investment Partners’s Nurix Therapeutics NRIX Stock Holding History

Ameritas Investment Partners’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$211K Buy
8,702
+566
+7% +$9.64K 0.01% 1367
2026
Q1 		$126K Hold
8,136
– – ﹤0.01% 1544
2025
Q4 		$154K Buy
8,136
+1,838
+29% +$26.4K ﹤0.01% 1419
2025
Q3 		$58.2K Sell
6,298
-1,047
-14% -$10.9K ﹤0.01% 2025
2025
Q2 		$83.7K Hold
7,345
– – ﹤0.01% 1871
2025
Q1 		$87.3K Hold
7,345
– – ﹤0.01% 1796
2024
Q4 		$138K Buy
7,345
+877
+14% +$20.1K ﹤0.01% 1561
2024
Q3 		$145K Buy
6,468
+539
+9% +$12.2K ﹤0.01% 1542
2024
Q2 		$124K Buy
5,929
+1,308
+28% +$20.4K ﹤0.01% 1596
2024
Q1 		$67.9K Hold
4,621
– – ﹤0.01% 1969
2023
Q4 		$47.7K Hold
4,621
– – ﹤0.01% 2195
2023
Q3 		$36.3K Buy
4,621
+1,296
+39% +$11.8K ﹤0.01% 2267
2023
Q2 		$33.2K Hold
3,325
– – ﹤0.01% 2281
2023
Q1 		$29.5K Hold
3,325
– – ﹤0.01% 2283
2022
Q4 		$42.1K Hold
3,325
– – ﹤0.01% 2182
2022
Q3 		$43K Hold
3,325
– – ﹤0.01% 2094
2022
Q2 		$42K Buy
3,325
+869
+35% +$9.85K ﹤0.01% 2103
2022
Q1 		$34K Hold
2,456
– – ﹤0.01% 2282
2021
Q4 		$71K Hold
2,456
– – ﹤0.01% 1906
2021
Q3 		$74K Hold
2,456
– – ﹤0.01% 1880
2021
Q2 		$65K Buy
2,456
+509
+26% +$14.9K ﹤0.01% 2009
2021
Q1 		$61K Buy
1,947
+1,001
+106% +$37.9K ﹤0.01% 1964
2020
Q4 		$31K Hold
946
– – ﹤0.01% 2257
2020
Q3 		$33K Buy
+946
New +$23.8K ﹤0.01% 2095

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Rubric Capital Management (New York)
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ameritas Investment Partners's NRIX Position: Q2 2026 in Review

Ameritas Investment Partners increased its Nurix Therapeutics (NRIX) stake by 7% in Q2 2026, buying an estimated $9.64K and bringing the position to 8,702 shares worth $211K. The position accounts for 0.01% of the portfolio, ranked #1367.

Ameritas Investment Partners first reported a position in NRIX in Q3 2020 and has held it in 24 quarters since. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Ameritas Investment Partners held 8,702 shares of Nurix Therapeutics worth $211K as of Q2 2026.
  • Ameritas Investment Partners bought 566 Nurix Therapeutics shares in Q2 2026, an estimated $9.64K.
  • Nurix Therapeutics made up 0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #1367 holding.
  • Ameritas Investment Partners first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.